Regulatory MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priority Pharmaceutical Business ReviewThe treatment targets adult patients with ES-SCLC who have experienced disease progression on or after platinum-based chemotherapy.RegulatoryOncologyRead full story pharminent April 14, 2026 (Last updated: April 14, 2026) Pharmaceutical Business Review The treatment targets adult patients with ES-SCLC who have experienced disease progression on or after platinum-based chemotherapy. RegulatoryOncologyRead full story Post navigation Previous: Travere claims first FDA OK in rare kidney disease FSGSNext: Travere Therapeutics gains FDA approval for sparsentan in FSGS Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026